Research compounds
Orexin A
Hypocretin-1
Orexin A is a hypothalamic neuropeptide governing wakefulness and arousal. Loss of orexin-producing neurons causes narcolepsy type 1, and the orexin system is the target of an entire approved insomnia drug class.
Also known as: hypocretin 1, orexin-A, OX-A
- Status
- Orexin A is a research compound and not approved by the FDA for human use.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- Short; rapidly degraded in plasma.
- How it's taken
- Intranasal or intracerebroventricular in the research setting
- Mechanism
- Cognitive / mood
How Orexin A works
Orexin A is produced by a small population of lateral hypothalamic neurons and signals at OX1R and OX2R receptors to stabilise wakefulness, promoting activity in the monoaminergic and cholinergic arousal systems. It also links arousal to energy state — orexin neurons are sensitive to glucose, leptin and ghrelin, which is why hunger promotes wakefulness.
What research has looked at
- The discovery that narcolepsy type 1 results from autoimmune destruction of orexin neurons was a decisive advance in sleep medicine.
- It produced a genuinely new drug class in reverse: dual orexin receptor antagonists such as suvorexant, lemborexant and daridorexant are approved for insomnia and work by blocking this system.
- Orexin receptor agonists are now in late-stage trials for narcolepsy, aiming to replace the missing signal directly rather than stimulate arousal non-specifically.
- Intranasal orexin A has been investigated for cognitive and alertness effects in sleep-deprived primates and humans.
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- No orexin agonist is approved; the approved drugs in this system are antagonists, doing the opposite of what performance-oriented users would want. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- Peptide orexin A crosses the blood-brain barrier poorly, which is why intranasal delivery was investigated and why systemic administration is not straightforward.
- Manipulating a core arousal system carries risk of disrupted sleep architecture, and the long-term consequences are unstudied.
- Cardiovascular and autonomic effects follow from orexin's role in sympathetic regulation.
Sources
- PubMed research on orexin hypocretin narcolepsy wakefulness · NIH · National Library of Medicine
- DrugBank record for orexin A · DrugBank
- Active clinical trials for orexin A · U.S. National Library of Medicine
Track Orexin A in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Orexin A FAQ
What is Orexin A?
Orexin A is a hypothalamic neuropeptide governing wakefulness and arousal. Loss of orexin-producing neurons causes narcolepsy type 1, and the orexin system is the target of an entire approved insomnia drug class.
How does Orexin A work?
Orexin A is produced by a small population of lateral hypothalamic neurons and signals at OX1R and OX2R receptors to stabilise wakefulness, promoting activity in the monoaminergic and cholinergic arousal systems. It also links arousal to energy state — orexin neurons are sensitive to glucose, leptin and ghrelin, which is why hunger promotes wakefulness.
Is Orexin A FDA approved?
No. Orexin A is a research compound and not approved by the FDA for human use. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of Orexin A?
Reported half-life: Short; rapidly degraded in plasma.
How is Orexin A taken?
Intranasal or intracerebroventricular in the research setting.
What side effects have been reported with Orexin A?
Reported in the sources: No orexin agonist is approved; the approved drugs in this system are antagonists, doing the opposite of what performance-oriented users would want. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; Peptide orexin A crosses the blood-brain barrier poorly, which is why intranasal delivery was investigated and why systemic administration is not straightforward; Manipulating a core arousal system carries risk of disrupted sleep architecture, and the long-term consequences are unstudied; Cardiovascular and autonomic effects follow from orexin's role in sympathetic regulation.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.